H1617: Stem Cell Therapy
Legislative Summary
Authorizes allopathic physicians & osteopathic physicians to perform stem cell therapy not approved by United States Food & Drug Administration; specifies requirements for stem cells that may be used by allopathic physicians & osteopathic physicians; requires allopathic physicians & osteopathic physicians to adhere to applicable current good manufacturing practices in performance of such therapies; prohibits allopathic physicians & osteopathic physicians from obtaining stem cells for therapies from facilities failing to meet certain requirements; requires allopathic physicians & osteopathic physicians to include certain terms in contracts or agreements with facilities producing stem cells for therapies; requires allopathic physicians & osteopathic physicians to include specified notice in any form of advertisement; provides requirements for such notice; requires allopathic physicians & osteopathic physicians to obtain signed consent form from patient or his or her representative before performing therapy; specifies requirements for consent form; requires Board of Medicine & Board of Osteopathic Medicine to adopt rules, respectively.
Demographic Impact
Overall analysis of equity impact
Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
